IAN-Led Round Injects ₹6.5 Cr into Lamark Biotech to Tackle Cold-Chain Gaps in BioPharma

• Lamark Biotech Raises ₹6.5 Crore in Pre-Series A Round Led by IAN Group, Powered by BioAngels

Lamark Biotech, an innovation-led biopharma startup, raised ₹6.5 crore in a Pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr. Vinayender Tulla, Dr. Nita Roy, and Mr. Venkataraman KNK, domain experts of IAN’s angel investors led the round.

Founded in 2018 by Dr. Vaibhav Bhatia, a entrepreneur and Biochemist by training, Lamark Biotech is reimagining drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong™ platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Lamark addresses a critical gap in the biologics ecosystem: reducing the cold-chain dependency.

Vaibhav Bhatia, Founder and CEO of Lamark Biotech, said, “This funding round with IAN marks a turning point for Lamark, but also for the patients across the planet. We’re accelerating our thermostable insulin program and expanding ProteoStrong™ to more critical therapeutics using this resource. Our priority is clear- make safe and high-efficacy biologics for all. We believe, ‘if it is not accessible, it not a medicine”

Padmaja Ruparel, Co-founder, IAN Group, said, “Investment in Lamark represents IAN’s investment strategy to invest and grow innovations that solve real problems. The solution is critical in low-resource environments, with Lamark's thermostable biologics which can make critical treatments accessible at a low cost for millions of people, both in India and globally.”

The Ahmedabad-headquartered startup, leveraging R&D base of Venture Center, NCL-innovation park in Pune, is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions, ideal for underserved regions where cold storage infrastructure is limited.

With its lead program, InsulinStrong, Lamark is targeting the ₹4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. expanding its platform into diabetic eye disease and cancer immunotherapy. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Amid growing global efforts to enhance healthcare access and strengthen drug delivery infrastructure, Lamark Biotech is strategically positioned to lead the next generation of biopharmaceutical innovation through its robust, cold-chain-independent solutions.

About Lamark Biotech:

Lamark Biotech is an innovation-driven biopharmaceutical startup focused on developing proprietary formulations of biologics for chronic and life-altering diseases. The company’s core expertise lies in stabilizing complex therapeutic proteins and peptides to improve their shelf-life, efficacy, and patient convenience. With a strong emphasis on global healthcare, it addresses critical gaps in formulation technology, including ultra-stable, temperature-resilient drug delivery systems for indications such as diabetes, ophthalmic disorders, and cancer immunotherapy.

About IAN Group:

IAN Group is the country’s single largest platform for seed and early stage investment platform with IAN Angel Network, BioAngels and IAN Fund I and IAN Alpha Fund enabling entrepreneurs to raise from Rs. 50 lakhs to Rs. 50 crores. The platform brings money, mentoring from successful entrepreneurs and global market access. The platform is sector-agnostic and has funded innovative start-ups across 19 sectors in India and 7 other countries, thereby growing the global footprint of companies. IAN has been listed by Forbes as one of iconic business and economic events of Independent India, over 75 years along with LIC, NASSCOM, RBI, Naukri.com amongst others.